Announced Date: 2024-05-21 (May 21, 2024)
Seller: ProfoundBio (China)
Buyer: Genmab A/S (Denmark)
Payment: USD 1.8 billion in cash
.
Key Assets: Three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate technology platforms.
Lead Asset: Rinatabart sesutecan (Rina-S, GEN1184, PRO1184)
Asset Modality and Target: FRα-targeted, Topo1 ADC
Potential Indication: Treatment of ovarian cancer and other FRα-expressing solid tumors
Current Stage: Phase 1/2 clinical trial
.
About ProfoundBio
ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple ADC drug candidates targeting solid tumors and hematological malignancies.
The company’s disclosed development pipeline consists of rinatabart sesutecan (Rina-S; PRO1184), an ADC targeting FRα; PRO1160, an ADC targeting CD70; PRO1107, an ADC targeting PTK7; and PRO1286, a bispecific ADC targeting EGFR and cMET. ProfoundBio is headquartered in Seattle, Washington with an R&D center of innovation in Suzhou, China.
.
Link:
. Genmab Completes Acquisition of ProfoundBio – Genmab A/S
. Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio – Genmab A/S
.
Note:
Chinese Name of ProfoundBio, 普方生物
